| Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (NCT05492409) | AO GENERIUM | 2022-03-28 |
| Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (NCT05220878) | AO GENERIUM | 2021-09-09 |
| A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 (NCT04132050) | Kissei Pharmaceutical Co., Ltd. | 2019-12-24 |
| Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? (NCT04128358) | Assiut University | 2019-11-01 |
| Safety and Efficacy of Fecal Microbiota Transplantation (NCT04014413) | Chinese University of Hong Kong | 2019-07-15 |
| Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level (NCT03864796) | Assiut University | 2019-03-01 |
| Investigation on a Dynamic Cohort of Italian Patients With Active ITP (NCT03465020) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2018-10-15 |
| The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. (NCT03412188) | Nayera Hazaa Elsherif | 2018-08-01 |
| Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT (NCT03421392) | Nantes University Hospital | 2018-01-01 |
| Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools) (NCT03123497) | University Hospital, Angers | 2017-04-12 |
| MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (NCT01609452) | Anthera Pharmaceuticals | 2015-12-01 |
| Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) (NCT01443351) | Zealand University Hospital | 2015-03-01 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases (NCT01988506) | Assistance Publique - Hôpitaux de Paris | 2014-01-06 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (NCT01882127) | Shandong University | 2013-02-01 |
| rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP (NCT01734044) | Shandong University | 2012-07-01 |
| Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura (NCT01571349) | Samsung Medical Center | 2012-04-01 |
| A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (NCT01433978) | Eisai Inc. | 2012-03-26 |
| Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (NCT01520909) | GlaxoSmithKline | 2012-03-01 |
| Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (NCT01444417) | Amgen | 2012-01-01 |
| A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (NCT01549054) | Eisai Inc. | 2012-01-01 |
| rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (NCT01525836) | Shandong University | 2011-05-01 |
| Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP (NCT01805648) | Peking Union Medical College | 2011-02-01 |
| Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim (NCT01143038) | Amgen | 2010-11-30 |
| Single Incision Versus Standard Laparoscopic Splenectomy (NCT01276561) | Children's Mercy Hospital Kansas City | 2009-10-01 |
| Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) (NCT00907478) | Amgen | 2009-08-11 |
| Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag (NCT00888901) | Ingrid Pabinger, MD | 2009-05-01 |
| Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias (NCT00749112) | Hospital Universitario Dr. Jose E. Gonzalez | 2008-08-01 |
| IGIV Study for Chronic ITP Patients Ages 3-70 (NCT00511147) | Grifols Biologicals, LLC | 2008-05-01 |
| Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) (NCT00828750) | GlaxoSmithKline | 2008-05-01 |
| P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (NCT00603642) | Amgen | 2007-10-01 |
| A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. (NCT00475423) | Hoffmann-La Roche | 2007-05-01 |
| Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 (NCT00625443) | Eisai Inc. | 2007-05-01 |
| Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura (NCT00415532) | Amgen | 2006-12-01 |
| Sirolimus for Autoimmune Disease of Blood Cells (NCT00392951) | Children's Hospital of Philadelphia | 2006-12-01 |
| Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (NCT00454857) | Amgen | 2006-05-01 |
| High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP (NCT00451594) | Cooperative Study Group A for Hematology | 2005-09-01 |
| Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) (NCT00244257) | Genzyme, a Sanofi Company | 2005-08-01 |
| Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology (NCT00861224) | Amgen | 2005-08-01 |
| A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) (NCT00770562) | Hoffmann-La Roche | 2005-07-01 |
| AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy (NCT00102336) | Amgen | 2005-04-07 |
| AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy (NCT00102323) | Amgen | 2005-03-29 |
| An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP (NCT00508820) | Amgen | 2005-02-01 |
| Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D (NCT00128882) | University of Aarhus | 2004-11-01 |
| Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (NCT01713855) | Neufeld, Ellis J, MD, PhD | 2004-10-01 |
| Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (NCT00116688) | Amgen | 2004-08-01 |
| The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) (NCT00909077) | Copenhagen University Hospital at Herlev | 2004-08-01 |
| Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) (NCT00111475) | Amgen | 2002-07-01 |